Will Gilead take over the hepatitis C market, too?

Gilead has attracted attention of the industry if it would continue the success of its domestic antivirus treatment even in the hepatitis C treatment market.

Recently, Gilead has actively established a hepatitis C product pipeline by acquiring ‘Harvoni(sofosbuvir+ledipasivir),’ a genotype 1 hepatitis C treatment, from the Ministry of Food and Drug Safety along with ‘Sovaldi(generic name: sofos...